FY2025 EPS Estimate for Vera Therapeutics Lowered by Analyst

Vera Therapeutics, Inc. (NASDAQ:VERA) – Research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Vera Therapeutics in a note issued to investors on Wednesday, May 7th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($2.74) per share for the year, down from their prior forecast of ($2.53). Cantor Fitzgerald currently has a “Overweight” rating and a $100.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share.

Other analysts have also recently issued research reports about the company. Guggenheim lifted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Wedbush cut their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday. HC Wainwright initiated coverage on Vera Therapeutics in a report on Monday, May 5th. They set a “buy” rating and a $75.00 target price on the stock. Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Vera Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $63.33.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA opened at $21.77 on Friday. The company has a market cap of $1.39 billion, a P/E ratio of -8.34 and a beta of 1.28. The business has a fifty day simple moving average of $24.22 and a 200-day simple moving average of $34.68. Vera Therapeutics has a 52 week low of $18.53 and a 52 week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the firm earned ($0.56) EPS.

Institutional Trading of Vera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG grew its position in shares of Vera Therapeutics by 10.2% in the 1st quarter. Deutsche Bank AG now owns 892,859 shares of the company’s stock worth $21,446,000 after acquiring an additional 82,483 shares in the last quarter. Thornburg Investment Management Inc. lifted its position in shares of Vera Therapeutics by 12.8% in the 1st quarter. Thornburg Investment Management Inc. now owns 66,572 shares of the company’s stock worth $1,599,000 after buying an additional 7,568 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Vera Therapeutics in the 1st quarter valued at about $252,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Vera Therapeutics by 19.7% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company’s stock valued at $229,000 after buying an additional 1,572 shares during the last quarter. Finally, TD Asset Management Inc raised its stake in Vera Therapeutics by 9.4% during the first quarter. TD Asset Management Inc now owns 252,164 shares of the company’s stock worth $6,057,000 after acquiring an additional 21,606 shares during the period. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.